Navidea Biopharmaceuticals (NAVB) 10-K2012 FY Annual report

Filed: 18 Mar 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abstract, Academy, adult, affirmed, albumin, alleviate, Amersham, Appendix, article, asAlzheimer, atrophy, behavior, Canadian, Casebier, CI, CMS, cohort, color, compromise, Conference, confusion, conservatively, Cornelia, cornerstone, CRL, currentlydeveloping, customary, cyber, DaTscan, DaTScanTM, deadline, deadlock, denying, disorder, dispute, distinct, DOI, downtime, Downtown, drawn, drew, duringthe, earliest, Eckert, elderly, Enzymedica, epithelial, false, forum, Germany, gold, Guild, Haber, HARDSHIP, HIPAA, idiopathic, imposition, includingClinical, incorrect, ineffectual, inlate, irrevocably, journalClinical, Ladenburg, LMU, lt, Ludwig, malfeasance, Maximillian, military, misdiagnosed, mistaken, MKT, motor, mouth, Munich, Nanocoll, nanocolloid, nationwide, Nordion, nutraceutical, Obama, obsolescence, ofNeurology, older, Oncologyand, OsoBio, Outpatient, outsource, ovarian, palsy, parallel, Parkinsonian, PD, PDF, Pendleton, PEO, PFO, PhD, physical, Piramal, playing, Portability, Precursor, pressure, prevalence, privacy, proportion, radiolabeledpositron, Radiology, RAS, Regan, registereddirect, Reininger, Relief, reputation, resubmission, resubmitted, robust, rotating, round, Scioto, Senate, Sequoia, serum, spearheaded, Stephen, stolen, store, stored, supranuclear, Taxpayer, TcSC, Thalmann, theDegree, theJournal, theLocalization, transmission, tremor, triple, underwent, Underwriter, underwriting, underwritten, Vancouver, vascular, veteran, vulnerable, waive, Wavier, William, young, Zeigler

Removed: acknowledged, altered, annum, API, approvable, approximated, arena, Aschinger, attempted, Biocore, BLA, bound, capacity, characterization, club, combining, competitor, compute, CR, cycle, Cynthia, discontinue, discounting, doubtful, draft, establishment, finalizing, gave, Gochoco, hereinafter, hidden, indexed, ingredient, intraoperatively, joint, MAb, Marquette, master, matured, measuring, Miller, offered, original, penalty, practicing, preparing, pro, promise, proximity, rata, reconciliation, recurrent, released, repayable, repeat, restatement, retired, slightly, survivorship, tranche, UC, uncollectible, unsold, viability, viable, Walter

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

NAVB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PERIODIC FINANCIAL REPORT PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002,18 U.S.C. SECTION 1350

The undersigned hereby certifies that he is the duly appointed and acting Chief Executive Officer of Navidea Biopharmaceuticals, Inc. (the Company) and hereby further certifies as follows:

(1) The periodic report containing financial statements to which this certificate is an exhibitfully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the periodic report to which this certificate is an exhibitfairly presents, in all material respects, the financial condition and results of operations of the Company.

In witness whereof, the undersigned has executed and delivered this certificate as of the date set forth opposite his signature below.

March 18, 2013	/s/ Mark J. Pykett
	Mark J. Pykett, V.M.D., Ph.D.
	President and Chief Executive Officer